Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03504488 · ClinicalTrials.gov registry record · Phase 1
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
A Phase 1 study, sponsored by BioAtla.
- Completed
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
NCT03504488: Completed Phase 1 study, sponsored by BioAtla.
NCT03504488 is a Phase 1 study that has completed, run by BioAtla. The registered enrollment target is 132 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (120% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03504488, a Phase 1 study, has completed, sponsored by BioAtla.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
Study Summary
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
Primary Outcome
Assess dose limiting toxicity as defined in the protocol
Interventions
- BIOLOGICAL PD-1 inhibitor
- BIOLOGICAL CAB-ROR2-ADC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2018-06-27 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 1 |
What the finished NCT03504488 record still lists
NCT03504488 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (120% higher).
The record links to 0 conditions, and to 2 interventions - of which PD-1 inhibitor is the first listed.
NCT03504488 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03504488 about?
NCT03504488 is a clinical study titled "CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)". The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
What is the current status of trial NCT03504488?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2018-06-27. Estimated completion is 2024-12-30.
What interventions are being tested in trial NCT03504488?
The interventions under investigation include: PD-1 inhibitor (BIOLOGICAL), CAB-ROR2-ADC (BIOLOGICAL).
Who is sponsoring clinical trial NCT03504488?
This trial is sponsored by BioAtla, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03504488's enrollment target sits among peer trials
132 432nd of 2000 higher than 1,562 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI